— ATR 1072 is the company’s first precision cardiology program to enter the clinic — — Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease — SAN DIEGO, July 14, 2026…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
